Octreotide for medullary thyroid carcinoma associated diarrhoea

Area of Science:

• Oncology
• Gastroenterology
• Endocrinology

Background:

• Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor that can secrete hormones like calcitonin.
• Diarrhoea is a common and often debilitating symptom of metastatic MTC, significantly impacting patient quality of life.
• Refractory diarrhoea in MTC poses a significant clinical challenge, with limited effective treatment options.

Observation:

• A case study involving a 75-year-old male patient with metastatic medullary thyroid carcinoma presented with severe, refractory diarrhoea and faecal incontinence.
• The patient's symptoms were unresponsive to standard treatments, highlighting the need for alternative therapeutic strategies.
• Subcutaneous administration of octreotide, a somatostatin analogue, was initiated at a dosage of 100 micrograms three times daily.

Findings:

• Octreotide treatment led to a sustained and significant improvement in the patient's diarrhoea.
• Faecal incontinence resolved completely during the course of octreotide therapy.
• Importantly, octreotide administration did not reduce the elevated calcitonin levels, suggesting a symptomatic rather than a direct anti-tumor effect on hormone secretion.

Implications:

• Octreotide represents a viable and effective symptomatic treatment option for patients suffering from refractory diarrhoea associated with medullary thyroid carcinoma.
• This case highlights the potential of somatostatin analogues in managing debilitating gastrointestinal symptoms in advanced MTC.
• Further investigation into the role of octreotide for symptom management in MTC is warranted to improve patient outcomes and quality of life.